600511

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Sinopharm Group Co ( (HK:1099) ).

Sinopharm Group has disclosed key unaudited first-quarter figures for its Shanghai-listed subsidiary China National Medicines Corporation, showing steady year-on-year revenue growth and modest improvement in profitability. Revenue for the three months to 31 March 2026 rose 6.63% to RMB 13.56 billion, while net profit attributable to shareholders increased 3.32% to RMB 474 million and earnings per share inched up to RMB 0.6286.

Underlying performance excluding non-recurring items also improved, yet net cash flow from operating activities deepened into a negative RMB 3.59 billion, highlighting working-capital or collection pressures despite profit growth. Total assets slipped 1.39% from year-end to RMB 36.18 billion, while equity attributable to shareholders rose 2.70%, indicating a strengthening capital base even as returns on equity edged down slightly, a mix that investors will weigh against cash flow weakness in assessing the subsidiary’s operational quality.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

More about Sinopharm Group Co

Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical conglomerate with listed subsidiaries engaged in the manufacture, distribution and sale of medicines and related healthcare products. Through China National Medicines Corporation Ltd. (SINOPHARM CNCM), whose A shares trade in Shanghai, the group targets the domestic pharmaceutical market across hospital, retail and institutional channels.

Average Trading Volume: 5,621,000

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$63.79B